TransCode Therapeutics (RNAZ) Competitors

$6.18 +0.01 (+0.16%)

Closing price 03:58 PM Eastern

Extended Trading

$6.06 -0.12 (-1.94%)

As of 06:19 PM Eastern

RNAZ vs. OTLK, LTRN, AYTU, VTGN, and MRKR

Should you buy TransCode Therapeutics stock or one of its competitors? MarketBeat compares TransCode Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with TransCode Therapeutics include Oncobiologics (OTLK), Lantern Pharma (LTRN), Aytu BioPharma (AYTU), VistaGen Therapeutics (VTGN), and Marker Therapeutics (MRKR). These companies are all part of the "pharmaceutical products" industry.

How does TransCode Therapeutics compare to Oncobiologics?

Oncobiologics (NASDAQ:OTLK) and TransCode Therapeutics (NASDAQ:RNAZ) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and risk.

Oncobiologics presently has a consensus price target of $4.50, suggesting a potential upside of 1,870.23%. Given Oncobiologics' stronger consensus rating and higher possible upside, research analysts clearly believe Oncobiologics is more favorable than TransCode Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncobiologics	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
TransCode Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

TransCode Therapeutics has lower revenue, but higher earnings than Oncobiologics. Oncobiologics is trading at a lower price-to-earnings ratio than TransCode Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncobiologics	$1.35M	20.45	-$62.42M	-$1.17	N/A
TransCode Therapeutics	N/A	N/A	-$34.66M	-$50.33	N/A

In the previous week, Oncobiologics had 2 more articles in the media than TransCode Therapeutics. MarketBeat recorded 3 mentions for Oncobiologics and 1 mentions for TransCode Therapeutics. TransCode Therapeutics' average media sentiment score of 1.08 beat Oncobiologics' score of -1.00 indicating that TransCode Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Oncobiologics	Negative
TransCode Therapeutics	Positive

Oncobiologics' return on equity of 0.00% beat TransCode Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oncobiologics	N/A	N/A	-291.28%
TransCode Therapeutics	N/A	-875.35%	-50.36%

Oncobiologics has a beta of 0.32, suggesting that its stock price is 68% less volatile than the broader market. Comparatively, TransCode Therapeutics has a beta of 1.39, suggesting that its stock price is 39% more volatile than the broader market.

11.2% of Oncobiologics shares are owned by institutional investors. 2.8% of Oncobiologics shares are owned by insiders. Comparatively, 0.0% of TransCode Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Oncobiologics beats TransCode Therapeutics on 9 of the 14 factors compared between the two stocks.

How does TransCode Therapeutics compare to Lantern Pharma?

Lantern Pharma (NASDAQ:LTRN) and TransCode Therapeutics (NASDAQ:RNAZ) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, dividends, profitability, valuation, earnings, risk and institutional ownership.

Lantern Pharma has a beta of 2.1, indicating that its share price is 110% more volatile than the broader market. Comparatively, TransCode Therapeutics has a beta of 1.39, indicating that its share price is 39% more volatile than the broader market.

28.6% of Lantern Pharma shares are held by institutional investors. 8.5% of Lantern Pharma shares are held by company insiders. Comparatively, 0.0% of TransCode Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Lantern Pharma is trading at a lower price-to-earnings ratio than TransCode Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantern Pharma	N/A	N/A	-$17.12M	-$1.45	N/A
TransCode Therapeutics	N/A	N/A	-$34.66M	-$50.33	N/A

In the previous week, Lantern Pharma had 7 more articles in the media than TransCode Therapeutics. MarketBeat recorded 8 mentions for Lantern Pharma and 1 mentions for TransCode Therapeutics. Lantern Pharma's average media sentiment score of 1.11 beat TransCode Therapeutics' score of 1.08 indicating that Lantern Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
Lantern Pharma	Positive
TransCode Therapeutics	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantern Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
TransCode Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Lantern Pharma's return on equity of -198.34% beat TransCode Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantern Pharma	N/A	-198.34%	-129.08%
TransCode Therapeutics	N/A	-875.35%	-50.36%

Summary

Lantern Pharma beats TransCode Therapeutics on 8 of the 10 factors compared between the two stocks.

How does TransCode Therapeutics compare to Aytu BioPharma?

TransCode Therapeutics (NASDAQ:RNAZ) and Aytu BioPharma (NASDAQ:AYTU) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, risk, valuation, media sentiment, institutional ownership, earnings and profitability.

Aytu BioPharma has a consensus target price of $9.33, suggesting a potential upside of 348.72%. Given Aytu BioPharma's stronger consensus rating and higher probable upside, analysts clearly believe Aytu BioPharma is more favorable than TransCode Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TransCode Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Aytu BioPharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

33.5% of Aytu BioPharma shares are held by institutional investors. 0.0% of TransCode Therapeutics shares are held by company insiders. Comparatively, 4.9% of Aytu BioPharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Aytu BioPharma had 9 more articles in the media than TransCode Therapeutics. MarketBeat recorded 10 mentions for Aytu BioPharma and 1 mentions for TransCode Therapeutics. TransCode Therapeutics' average media sentiment score of 1.08 beat Aytu BioPharma's score of -0.08 indicating that TransCode Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
TransCode Therapeutics	Positive
Aytu BioPharma	Neutral

TransCode Therapeutics has a net margin of 0.00% compared to Aytu BioPharma's net margin of -60.17%. Aytu BioPharma's return on equity of -69.93% beat TransCode Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TransCode Therapeutics	N/A	-875.35%	-50.36%
Aytu BioPharma	-60.17%	-69.93%	-13.25%

TransCode Therapeutics has a beta of 1.39, meaning that its share price is 39% more volatile than the broader market. Comparatively, Aytu BioPharma has a beta of 0.28, meaning that its share price is 72% less volatile than the broader market.

Aytu BioPharma has higher revenue and earnings than TransCode Therapeutics. Aytu BioPharma is trading at a lower price-to-earnings ratio than TransCode Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TransCode Therapeutics	N/A	N/A	-$34.66M	-$50.33	N/A
Aytu BioPharma	$66.38M	0.34	-$13.56M	-$4.58	N/A

Summary

Aytu BioPharma beats TransCode Therapeutics on 11 of the 15 factors compared between the two stocks.

How does TransCode Therapeutics compare to VistaGen Therapeutics?

VistaGen Therapeutics (NASDAQ:VTGN) and TransCode Therapeutics (NASDAQ:RNAZ) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, analyst recommendations, risk, media sentiment, earnings and dividends.

VistaGen Therapeutics' return on equity of -109.72% beat TransCode Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
VistaGen Therapeutics	N/A	-109.72%	-89.62%
TransCode Therapeutics	N/A	-875.35%	-50.36%

TransCode Therapeutics has lower revenue, but higher earnings than VistaGen Therapeutics. VistaGen Therapeutics is trading at a lower price-to-earnings ratio than TransCode Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VistaGen Therapeutics	$490K	50.95	-$51.42M	-$1.89	N/A
TransCode Therapeutics	N/A	N/A	-$34.66M	-$50.33	N/A

VistaGen Therapeutics has a beta of 0.31, suggesting that its stock price is 69% less volatile than the broader market. Comparatively, TransCode Therapeutics has a beta of 1.39, suggesting that its stock price is 39% more volatile than the broader market.

78.4% of VistaGen Therapeutics shares are held by institutional investors. 2.9% of VistaGen Therapeutics shares are held by company insiders. Comparatively, 0.0% of TransCode Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

VistaGen Therapeutics currently has a consensus price target of $0.95, suggesting a potential upside of 50.77%. Given VistaGen Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe VistaGen Therapeutics is more favorable than TransCode Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VistaGen Therapeutics	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
TransCode Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, VistaGen Therapeutics had 1 more articles in the media than TransCode Therapeutics. MarketBeat recorded 2 mentions for VistaGen Therapeutics and 1 mentions for TransCode Therapeutics. TransCode Therapeutics' average media sentiment score of 1.08 beat VistaGen Therapeutics' score of 0.48 indicating that TransCode Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
VistaGen Therapeutics	Neutral
TransCode Therapeutics	Positive

Summary

VistaGen Therapeutics beats TransCode Therapeutics on 8 of the 13 factors compared between the two stocks.

How does TransCode Therapeutics compare to Marker Therapeutics?

TransCode Therapeutics (NASDAQ:RNAZ) and Marker Therapeutics (NASDAQ:MRKR) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, dividends, valuation, profitability, risk, earnings, institutional ownership and media sentiment.

22.4% of Marker Therapeutics shares are owned by institutional investors. 0.0% of TransCode Therapeutics shares are owned by insiders. Comparatively, 5.7% of Marker Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Marker Therapeutics had 1 more articles in the media than TransCode Therapeutics. MarketBeat recorded 2 mentions for Marker Therapeutics and 1 mentions for TransCode Therapeutics. Marker Therapeutics' average media sentiment score of 1.50 beat TransCode Therapeutics' score of 1.08 indicating that Marker Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
TransCode Therapeutics	Positive
Marker Therapeutics	Very Positive

Marker Therapeutics has a consensus target price of $10.00, indicating a potential upside of 619.42%. Given Marker Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Marker Therapeutics is more favorable than TransCode Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TransCode Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Marker Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

TransCode Therapeutics has a net margin of 0.00% compared to Marker Therapeutics' net margin of -343.03%. Marker Therapeutics' return on equity of -73.29% beat TransCode Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TransCode Therapeutics	N/A	-875.35%	-50.36%
Marker Therapeutics	-343.03%	-73.29%	-59.70%

TransCode Therapeutics has a beta of 1.39, suggesting that its share price is 39% more volatile than the broader market. Comparatively, Marker Therapeutics has a beta of 1.43, suggesting that its share price is 43% more volatile than the broader market.

Marker Therapeutics has higher revenue and earnings than TransCode Therapeutics. Marker Therapeutics is trading at a lower price-to-earnings ratio than TransCode Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TransCode Therapeutics	N/A	N/A	-$34.66M	-$50.33	N/A
Marker Therapeutics	$3.55M	6.53	-$12.16M	-$0.61	N/A

Summary

Marker Therapeutics beats TransCode Therapeutics on 12 of the 15 factors compared between the two stocks.

Get TransCode Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RNAZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RNAZ vs. The Competition

Export

Metric	TransCode Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5.86M	$2.99B	$6.25B	$12.23B
Dividend Yield	N/A	1.96%	2.80%	5.27%
P/E Ratio	-0.12	17.04	20.79	25.04
Price / Sales	N/A	251.21	531.21	72.17
Price / Cash	N/A	57.15	43.09	54.25
Price / Book	4.68	4.39	9.81	6.83
Net Income	-$34.66M	$74.99M	$3.55B	$335.69M
7 Day Performance	-8.17%	-4.89%	-2.07%	-2.03%
1 Month Performance	-29.77%	-8.30%	-3.90%	-1.90%
1 Year Performance	-7.76%	28.66%	29.39%	27.36%

TransCode Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RNAZ TransCode Therapeutics	0.5211 of 5 stars	$6.18 +0.2%	N/A	-24.4%	$5.86M	N/A	N/A	9	Positive News Earnings Report Gap Up
OTLK Oncobiologics	2.3595 of 5 stars	$0.24 +0.2%	$4.50 +1,751.9%	-86.9%	$25.21M	$1.35M	N/A	20	Negative News Earnings Report Upcoming Earnings Analyst Forecast
LTRN Lantern Pharma	0.9214 of 5 stars	$2.22 +7.5%	N/A	-9.6%	$24.83M	N/A	N/A	20	Positive News Earnings Report Gap Up
AYTU Aytu BioPharma	2.1831 of 5 stars	$2.28 -0.8%	$9.33 +309.0%	-1.4%	$24.64M	$66.38M	N/A	160	News Coverage Earnings Report Gap Up High Trading Volume
VTGN VistaGen Therapeutics	2.3166 of 5 stars	$0.62 -0.9%	$0.95 +54.2%	-75.8%	$24.41M	$490K	N/A	40

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RNAZ) was last updated on 5/19/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

TransCode Therapeutics (RNAZ) Competitors

RNAZ vs. OTLK, LTRN, AYTU, VTGN, and MRKR

How does TransCode Therapeutics compare to Oncobiologics?

Summary

How does TransCode Therapeutics compare to Lantern Pharma?

Summary

How does TransCode Therapeutics compare to Aytu BioPharma?

Summary

How does TransCode Therapeutics compare to VistaGen Therapeutics?

Summary

How does TransCode Therapeutics compare to Marker Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNAZ vs. The Competition

TransCode Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

TransCode Therapeutics (RNAZ) Competitors

RNAZ vs. OTLK, LTRN, AYTU, VTGN, and MRKR

How does TransCode Therapeutics compare to Oncobiologics?

Do analysts rate OTLK or RNAZ?

Which has better valuation & earnings, OTLK or RNAZ?

Does the media prefer OTLK or RNAZ?

Is OTLK or RNAZ more profitable?

Which has more volatility & risk, OTLK or RNAZ?

Do institutionals and insiders hold more shares of OTLK or RNAZ?

Summary

How does TransCode Therapeutics compare to Lantern Pharma?

Which has more volatility and risk, LTRN or RNAZ?

Do insiders and institutionals have more ownership in LTRN or RNAZ?

Which has higher earnings and valuation, LTRN or RNAZ?

Does the media favor LTRN or RNAZ?

Do analysts recommend LTRN or RNAZ?

Is LTRN or RNAZ more profitable?

Summary

How does TransCode Therapeutics compare to Aytu BioPharma?

Do analysts prefer RNAZ or AYTU?

Do institutionals & insiders hold more shares of RNAZ or AYTU?

Does the media refer more to RNAZ or AYTU?

Is RNAZ or AYTU more profitable?

Which has more risk & volatility, RNAZ or AYTU?

Which has better earnings & valuation, RNAZ or AYTU?

Summary

How does TransCode Therapeutics compare to VistaGen Therapeutics?

Is VTGN or RNAZ more profitable?

Which has stronger earnings and valuation, VTGN or RNAZ?

Which has more volatility & risk, VTGN or RNAZ?

Do insiders & institutionals hold more shares of VTGN or RNAZ?

Do analysts prefer VTGN or RNAZ?

Does the media favor VTGN or RNAZ?

Summary

How does TransCode Therapeutics compare to Marker Therapeutics?

Do institutionals & insiders have more ownership in RNAZ or MRKR?

Does the media favor RNAZ or MRKR?

Do analysts prefer RNAZ or MRKR?

Is RNAZ or MRKR more profitable?

Which has more volatility and risk, RNAZ or MRKR?

Which has higher earnings and valuation, RNAZ or MRKR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNAZ vs. The Competition

TransCode Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools